Coincidence of Autoimmune Diabetes Mellitus and Familial Partial Lipodystrophy
Abstract
Familial partial lipodystrophy (FPLD) is a rare genetic disorder leading to adipose tissue deficiency/redistribution and metabolic dysregulation with insulin resistance, diabetes mellitus, and dyslipidemia. Coincidence of FPLD and autoantibody-positive type 1 diabetes has not been published yet. We identified a female patient with the initial diagnosis of autoantibody-positive type 1 diabetes who developed severe insulin resistance with daily insulin doses up to 300 IU/d, acanthosis nigricans, polycystic ovary syndrome, hyperphagia, myalgia, and dyslipidemia. Since her phenotype was suspicious for FPLD, genetic testing was initiated. It revealed a heterozygous missense variant at hot spot codon c.1444 within Lamin A/C (LMNA) (p.Arg482Trp). Insulin resistance and hyperphagia improved during treatment with the glucagon-like peptide 1-receptor agonist semaglutide in addition to insulin therapy. Thus, we report about a patient with FPLD2 and concomitant type 1 diabetes. This case demonstrates that coincidence of these 2 severe metabolic dysregulations challenges diagnosis, management, and treatment but demands awareness in our health care system for rare endocrine diseases to improve quality of care.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.